Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Paul Hartmann AG
  6. News
  7. Summary
    PHH2   DE0007474041

PAUL HARTMANN AG

(PHH2)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Paul Hartmann : HARTMANN adjusts forecast for fiscal year 2020

12/18/2020 | 07:59am EDT
  • All core segments of HARTMANN are faced with coronavirus-related challenges. Most segments are experiencing weak to negative growth. Sales of disinfectants and personal protective equipment have, on the other hand, increased considerably.
  • Up to September 2020, there has been an overall organic sales growth of 15.4% and significant improvement in earnings.
  • The new forecast for 2020 adjusted EBITDA is now EUR 280 to 320 million.
  • Outlook: Implementation of transformation program and ongoing consequences of coronavirus pandemic are expected to burden sales and earnings.

In the first nine months of 2020, the HARTMANN GROUP generated sales revenues of EUR 1,820 million (previous year: EUR 1,615 million), organic sales growth of 15.4% and an adjusted EBITDA of EUR 207.1 million (adjusted EBITDA margin of 11.4%). During this period, the coronavirus pandemic continued to be the dominant factor in the development of the business.


Coronavirus-related challenges in the core segments:
Due to a considerable rise in the number of COVID-19 infections since September, HARTMANN's core segments are facing significant challenges. On the one hand, there is a temporary strong increase in demand for disinfectants and personal protective equipment, which the company is already meeting in the best possible way, i.e. with measures to expand production capacities and secure supply chains. On the other hand, challenges also stem from the postponement of non-urgent surgeries, which results in a decline in business, for example in sterile surgical products and other product groups in Wound Management. These challenges are reflected in the development of the core segments.

  • The organic sales decline of 4.6% in the Wound Management segment is primarily due to declining business with classic dressing materials.
  • Sales in the Incontinence Management segment were on a par with the previous year with organic growth of 0.2%.
  • The strong organic sales growth of 64.4% in the Infection Management segment is mainly due to strong coronavirus-related demand for disinfectants and personal protective equipment, such as masks and examination gloves. Sales of pre-packaged surgical procedure trays, on the other hand, declined significantly due to postponed surgeries.


Forecast 2020:
The forecast for the current year as a whole was raised today due to the continuing coronavirus-related strong demand for disinfectants and personal protective equipment. HARTMANN now expects adjusted EBITDA of EUR 280 to EUR 320 million for 2020 and continued strong organic sales growth.


Outlook:
There is a high degree of forecast uncertainty due to the unclear further course of the coronavirus pandemic and its economic consequences. HARTMANN therefore currently expects the following developments:

  • The tendentially positive special effects in individual product groups observed in the exceptional year of 2020 will be less pronounced in the future.
  • Negative effects on HARTMANN's business performance during and particularly after the coronavirus pandemic are to be expected, e.g. due to increased budgetary pressure on healthcare systems.
  • The investment requirements for the implementation of the transformation program in combination with the aforementioned effects of the coronavirus pandemic are expected to have a negative impact on sales and earnings in the following year.


Quote Britta Fünfstück, CEO, HARTMANN GROUP:

Overall, the challenging market conditions for the other business segments due to the coronavirus pandemic can be compensated for by considerably increased demand for disinfectants and personal protective equipment.'

Download
Press contact
Dominik Plonner
presse@hartmann.info
+49-7321-36 1308

Disclaimer

Paul Hartmann AG published this content on 10 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 December 2020 12:58:00 UTC


© Publicnow 2020
All news about PAUL HARTMANN AG
08/11PAUL HARTMANN : Q2 2021 Quarterly Information
PU
08/11PAUL HARTMANN : HARTMANN's sales and earnings decline compared with previous quarters, as ..
PU
08/11Paul Hartmann AG Reports Earnings Results for the Half Year Ended June 30, 2021
CI
07/13PAUL HARTMANN : HARTMANN becomes hygiene partner of the Allianz Arena in Munich
PU
04/30PAUL HARTMANN : HARTMANN's dynamic growth in previous quarters slows noticeably in first q..
PU
03/23Paul Hartmann Ag Reports Earnings Results for the Full Year Ended December 31, 2020
CI
02/23PAUL HARTMANN : Changes in the Management Board of the HARTMANN GROUP
PU
2020PAUL HARTMANN : HARTMANN adjusts forecast for fiscal year 2020
PU
2020PAUL HARTMANN : Quarterly Information 2020 Q3
PU
2020PAUL HARTMANN : HARTMANN raises forecast due to temporary effects of coronavirus pandemic
PU
More news
Financials
Sales 2020 2 440 M 2 836 M 2 836 M
Net income 2020 106 M 124 M 124 M
Net cash 2020 169 M 197 M 197 M
P/E ratio 2020 11,9x
Yield 2020 2,25%
Capitalization 1 279 M 1 489 M 1 486 M
EV / Sales 2019 0,45x
EV / Sales 2020 0,45x
Nbr of Employees 10 622
Free-Float 17,9%
Chart PAUL HARTMANN AG
Duration : Period :
Paul Hartmann AG Technical Analysis Chart | PHH2 | DE0007474041 | MarketScreener
Technical analysis trends PAUL HARTMANN AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Britta Fuenfstueck Chairman-Management Board & CEO
Stefan Müller Chief Financial Officer
Fritz-Jürgen Heckmann Chairman-Supervisory Board
Bernhard Wittmann Senior Vice President-Global Operations Management
Christine Geppert Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
PAUL HARTMANN AG1.12%1 489
ABBOTT LABORATORIES12.62%218 606
MEDTRONIC PLC3.97%163 906
BECTON, DICKINSON AND COMPANY-1.33%70 907
HOYA CORPORATION19.13%56 339
DEXCOM, INC.50.53%53 845